Cabernet Pharmaceuticals and Lilly in alliance to develop
patient-tailored therapeutic drugs
20 November 2008
Cabernet Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE:LLY)
today announced an alliance to further integrate pharmacogenetics into
Lilly’s drug-development efforts.
Pharmacogenetics, the study of the genetic basis for varying
individual response to medicines, helps to identify patient populations
most likely to benefit from specific medicines and, just as importantly,
those patients least likely to respond. Pharmacogenetic research also
helps to define which patient groups are more likely or less likely to
experience side effects.
Under the agreement, Cabernet consultants will join
clinical-development teams at Lilly to assist in applying
pharmacogenetics to selected development projects. Financial terms were
not disclosed.
“Pharmacogenetics has come of age,” said Stephen Eck, vice president,
Translational Medicine and Pharmacogenomics, at Lilly. “It is one of the
tools we increasingly bring to developing tailored therapeutics for
better-defined patient groups. The experience of Cabernet in applying
pharmacogenetics to drug development will supplement Lilly’s in-house
capabilities, providing us a flexible resource as we manage the dynamics
of our R&D pipeline.”
Allen D Roses, MD, president and chief executive officer of Cabernet,
said: “We are delighted to form an alliance with a company of Lilly’s
stature, a company that is committed to developing medicines that can be
used with greater precision. We look forward to working closely with
Lilly’s R&D organization to further our common mission of delivering the
right medicines at the right doses to the right patients.”
Bookmark this page